Applied Therapeutics Granted Fast Track Designation by FDA for AT-007 for Galactosemia
June 17, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, June 17, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
June 01, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, June 01, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics to Present at the UBS Global Healthcare Virtual Conference
May 19, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, May 19, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics Reports First Quarter 2021 Financial Results
May 11, 2021 07:00 ET
|
Applied Therapeutics
Phase 2 pilot study of AT-007 initiated in patients with SORD Deficiency NDA submission for AT-007 in Galactosemia expected no later than Q3 2021; commercial preparations ongoing Completion of...
Applied Therapeutics to Present Cross-Sectional Analysis of Galactosemia Disease Progression at 2021 Annual Clinical Genetics Meeting of the American College of Medical Genetics and Genomics
April 07, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, April 07, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics Reports Fourth Quarter and Year-End 2020 Financial Results
March 18, 2021 07:00 ET
|
Applied Therapeutics
AT-007 ACTION-Galactosemia Kids pediatric clinical study recently resumed following discussions with FDA On track to submit NDA for AT-007 in Galactosemia no later than Q3 2021; Commercial...
Applied Therapeutics to Host Virtual Rare Disease Forum
March 16, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics to Present at the Cowen and Barclays Investor Conferences
February 23, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, Feb. 23, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated...
Applied Therapeutics, Inc. Announces Closing of Public Offering
February 22, 2021 07:00 ET
|
Applied Therapeutics
NEW YORK, Feb. 22, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates...
Applied Therapeutics, Inc. Announces Pricing of Public Offering of 3,000,000 Shares of Common Stock
February 11, 2021 18:51 ET
|
Applied Therapeutics
NEW YORK, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates...